This week the Boston Biomedical Innovation Center (B-BIC) released a new web video that highlights their 'Commercialization Coaches' and other services in which B-BIC successfully differentiates from other grants. Kantum Pharma, dedicated to the prevention and treatment of Acute Kidney Injury, received its first B-BIC pilot grant in 2017. *The Boston Biomedical Innovation Center is a National Center for Accelerated Innovation funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number U54HL119145. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Share on Facebook
Share on Twitter
Preclinical results support the therapeutic potential of KB-1801 for the prevention of Cardiac Surgery-Associated Acute Kidney Injury and advancement...
Kantum Pharma founder to present preclinical data demonstrating beneficial effects of P2Y14 antagonist in Acute Kidney Injury at the American Society...